As of Jul 25, 2024, the VRTX stock has a PE ratio of 31.6. The calculation is based on the latest EPS of $15.58 and the stock price of $492.26 per share. An increase of 17% has been observed in the PE ratio compared to its average of 27.1 of the past four quarters.
The mean historical PE ratio of Vertex Pharmaceuticals over the last eight years is 53.28. The current 31.6 price-to-earnings ratio is 41% less than the historical average. Analyzing the last eight years, VRTX's PE ratio reached its highest point in the Sep 2017 quarter at 190.05, with a price of $152.04 and an EPS of $0.8. The Dec 2018 quarter saw the lowest point at 20.11, with a price of $165.71 and an EPS of $8.24.
Maximum annual increase: 137.74% in 2019
Maximum annual decrease: -85.78% in 2018
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 28.96 | 30.04% |
| 2022 | 22.27 | -7.82% |
| 2021 | 24.16 | 6.71% |
| 2020 | 22.64 | -52.65% |
| 2019 | 47.81 | 137.74% |
| 2018 | 20.11 | -85.78% |
| 2017 | 141.38 | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
VRTX's current PE ratio is higher than the 3 and 5-year averages, but it is under its 10-year average.
When compared to its peers ABBV and MRK, VRTX's PE ratio is lower, but it is higher than JNJ's and ENZN's.
| Stock name | PE ratio | Market cap |
|---|---|---|
| ENZN Enzon Pharmaceuticals Inc | 0.42 | $6.63M |
| JNJ Johnson & Johnson | 10.55 | $386.7B |
| VRTX Vertex Pharmaceuticals Inc | 31.81 | $127.88B |
| ABBV AbbVie Inc | 54.94 | $326.97B |
| MRK Merck & Co Inc | 137.65 | $317.26B |
| GILD Gilead Sciences Inc | 192.55 | $95.96B |
| BMY Bristol Myers Squibb Co | N/A | $102.27B |
| ENTA Enanta Pharmaceuticals Inc | N/A | $328.07M |
The price to earnings ratio for VRTX stock is 31.6 as of Jul 25, 2024.
Over the last 3 years, the average PE ratio for VRTX stock is 24.89.
Over the last 5 years, the average PE ratio for VRTX stock is 27.06.
The highest quarterly PE ratio in the last eight years has been 190.05 and it was in the Sep 2017 quarter.
VRTX's current price to earnings ratio is 41% below its 8-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Jul 25, 2024), Vertex Pharmaceuticals's share price is $492.26. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $15.58. Therefore, Vertex Pharmaceuticals's price to earnings ratio for today is 31.6. PE RATIO(31.6) = STOCK PRICE($492.26) / TTM EPS($15.58)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.